The aim of the current study was to detect EGFR mutations in plasma cfDNA of NSCLC patients that are longitudinally monitored during osimertinib therapy before the initiation of therapy and at progression of disease using the crystal dPCR technology and the naica® system. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.